tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Adma Biologics raises FY26 revenue view to at least $630M from up at least $625M

Consensus $637.85M. Raises FY26 adjusted EBITDA view to $355M from $340M. The company said, “ADMA‘s full-year 2025 and 2026 financial outlook reflects continued ASCENIV demand strength, yield-enhanced production efficiencies, and disciplined operational execution.”

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1